Products Research Area/Disease Metabolism CircuLex PCSK9-LDLR in vitro Binding Assay Kit

CircuLex PCSK9-LDLR in vitro Binding Assay Kit

CircuLex PCSK9-LDLR in vitro Binding Assay Kit.

Specifications:

Description

The CycLex Research Product CircuLex PCSK9-LDLR in vitro Binding Assay Kit can be used for screening inhibitors of PCSK9-LDLR interaction in vitro.

Target:	PCSK9-LDLR
Product Type:	Kit
Size:	96 Assays
Research Area / Disease:	Metabolism
Storage Temperature:	4°C
Regulatory Statement:	For Research Use Only. Not for use in diagnostic procedures.

Components

Microplate
Recombinant His-tagged PCSK9 wild type
Biotinylated anti-His-tag monoclonal antibody
Reaction Buffer
HRP-conjugated Streptavidin
Conjugate Dilution Buffer
10X Wash Buffer
Substrate Reagent
Stop Solution

Citations

(Yonsei Med J 2015 Jul 29)

References

Momtazi-Borojeni, Amir Abbas, et al. “Impact of PCSK9 Immunization on Glycemic Indices in Diabetic Rats.” Journal of Diabetes Research 2021 (2021).
Momtazi-Borojeni, Amir Abbas, et al. “PCSK9 immunization using nanoliposomes: preventive efficacy against hypercholesterolemia and atherosclerosis.” Archives of Medical Science: AMS 17.5 (2021): 1365.
Momtazi-Borojeni, Amir Abbas, et al. “Pre-clinical evaluation of the nanoliposomal antiPCSK9 vaccine in healthy non-human primates.” Vaccines 9.7 (2021): 749.
Oleaga, Carlota, et al. “Insights into the kinetics and dynamics of the furin-cleaved form of PCSK9.” Journal of lipid research 62 (2021).
Momtazi-Borojeni, Amir Abbas, et al. “Effects of immunisation against PCSK9 in mice bearing melanoma.” Archives of Medical Science 16.1 (2020): 189-199.
Mikaeeli, Sepideh, et al. “Functional analysis of natural PCSK 9 mutants in modern and archaic humans.” The FEBS Journal 287.3 (2020): 515-528.
Momtazi-Borojeni, Amir Abbas, et al. “Therapeutic effect of nanoliposomal PCSK9 vaccine in a mouse model of atherosclerosis.” BMC medicine 17.1 (2019): 1-15.
Momtazi-Borojeni, Amir Abbas, et al. “Long-term generation of antiPCSK9 antibody using a nanoliposome-based vaccine delivery system.” Atherosclerosis 283 (2019): 69-78.
Momtazi-Borojeni, Amir Abbas, et al. “Potential anti-tumor effect of a nanoliposomal antiPCSK9 vaccine in mice bearing colorectal cancer.” Archives of Medical Science 15.3 (2019): 559-569.
Ben Djoudi Ouadda, Ali, et al. “Ser-phosphorylation of PCSK9 (proprotein convertase subtilisin-kexin 9) by Fam20C (family with sequence similarity 20, member C) kinase enhances its ability to degrade the LDLR (low-density lipoprotein receptor).” Arteriosclerosis, thrombosis, and vascular biology 39.10 (2019): 1996-2013.
Zhang, D. W., Lagace, T. A., Garuti, R., Zhao, Z., McDonald, M., Horton, J. D., Cohen, J. C., and Hobbs, H. H. (2007) J. Biol. Chem. 282, 18602–18612
Cohen JC, Boerwinkle E, Mosley TH, Jr, Hobbs HH (2006) N Engl J Med 354, 1264–1272.
Cameron, J., Holla, O. L., Ranheim, T., Kulseth, M. A., Berge, K. E., and Leren, T. P. (2006) Hum. Mol. Genet. 15, 1551–1558
Berge KE, Ose L, Leren TP (2006) Arterioscler Thromb Vasc Biol 26:1094–1100.
Cohen JC, Boerwinkle E, Mosley TH, Jr, Hobbs HH (2006) N Engl J Med 354, 1264–1272.
Lagace, T. A., Curtis, D. E., Garuti, R., McNutt, M. C., Park, S. W., Prather, H. B., Anderson, N. N., Ho, Y. K., Hammer, R. E., and Horton, J. D. (2006) J. Clin. Investig. 116, 2995–3005
Allard D, Amsellem S, Abifadel M, Trillard M, Devillers M, Luc G, Krempf M, Reznik Y, Girardet JP, Fredenrich A, et al. (2005) Hum Mutat 26:497.
Rashid S, Curtis DE, Garuti R, Anderson NN, Bashmakov Y, Ho YK, Hammer RE, Moon YA, Horton JD (2005) Proc Natl Acad Sci USA 102:5374–5379.
Leren TP (2004) Clin Genet 65:419–422.
Maxwell KN, Breslow JL (2004) Proc Natl Acad Sci USA 101:7100–7105.
NG, Benjannet S, Wickham L, Marcinkiewicz J, Jasmin SB, Stifani S, Basak A, Prat A, Chretien M (2003) Proc Natl Acad Sci USA 100:928–933.
Abifadel M, Varret M, Rabes JP, Allard D, Ouguerram K, Devillers M, Cruaud C, Benjannet S, Wickham L, Erlich D, et al. (2003) Nat Genet 34:154–156.